Key Segments:
By Drug Class
-
Anticonvulsants
-
Tricyclic Antidepressants (TCA)
-
Opioids
-
Capsaicin
-
Others
By Application
-
Diabetic Neuropathy
-
Chemotherapy Induced Neuropathy
-
Sciatic Neuropathy
-
Others
By Route of Administration
-
Oral
-
Parenteral
By Distribution Channel
-
Hospital Pharmacy
-
Retail Pharmacy
-
Online Pharmacy
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Neuropathic Pain Market size was valued at USD 8.15 billion in 2025.
The market is expected to reach USD 18.07 billion by 2035.
The market is anticipated to grow at a compound annual growth rate (CAGR) of 8.29% from 2026 to 2035.
Key growth drivers include the rising prevalence of diabetes, cancer, nerve injuries, and age-related neurological disorders, along with increasing demand for advanced pain management therapies.
Common treatments include antidepressants, anticonvulsants, opioids, topical agents, and nerve stimulation therapies.